Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1)

J Allergy Clin Immunol. 2018 Jul;142(1):328-330.e2. doi: 10.1016/j.jaci.2018.02.045. Epub 2018 May 2.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azetidines / therapeutic use*
  • Candidiasis, Chronic Mucocutaneous / drug therapy*
  • Candidiasis, Chronic Mucocutaneous / genetics*
  • Female
  • Gain of Function Mutation
  • Humans
  • Immunologic Deficiency Syndromes / complications
  • Immunologic Deficiency Syndromes / drug therapy
  • Immunologic Deficiency Syndromes / genetics
  • Janus Kinase Inhibitors / therapeutic use*
  • Purines
  • Pyrazoles
  • STAT1 Transcription Factor / genetics*
  • Sulfonamides / therapeutic use*
  • Young Adult

Substances

  • Azetidines
  • Janus Kinase Inhibitors
  • Purines
  • Pyrazoles
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • Sulfonamides
  • baricitinib